-
Sector Analysis
Multiple Sclerosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Multiple Sclerosis market through 2034. GlobalData estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion...
-
Sector Analysis
Multiple Sclerosis Epidemiology Analysis and Forecast to 2034
Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremors, muscle spasms, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people aged 15–60 years. The diagnosis of MS depends upon patients’ symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently,...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" provides an overview of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers...
-
Sector Analysis
Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Idiopathic Hypersomnia Therapeutics. - GlobalData epidemiologists estimate that there were 282,225 diagnosed prevalent cases of Idiopathic Hypersomnia (IH) in 2024, which is expected to increase slightly to 288,583 diagnosed prevalent cases by 2029. - Currently, the IH market has only one approved symptomatic relief therapy, and no disease-modifying therapies are available in the market. - The IH pipeline holds 11 molecules, with no assets in the...
-
Sector Analysis
Narcolepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Narcolepsy Therapeutics. - GlobalData epidemiologists estimate that there were 735,082 diagnosed prevalent cases of Narcolepsy in 2024, which is expected to increase slightly to 761,297 diagnosed prevalent cases by 2029. - Currently, the narcolepsy market is saturated with generic drugs, and few innovative therapies are available in the market. - The narcolepsy pipeline holds 28 molecules, with no assets in the pre-registration stage, five assets in...
-
Product Insights
Insomnia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Insomnia - Global Clinical Trials Review, 2025" provides an overview of Insomnia Clinical trials scenario. This report provides top line data relating to the clinical trials on Insomnia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Friedreich Ataxia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Friedreich Ataxia - Global Clinical Trials Review, 2025" provides an overview of Friedreich Ataxia Clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Progressive Supranuclear Palsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Progressive Supranuclear Palsy therapeutics. GlobalData epidemiologists estimate that there will be 263,657 diagnosed prevalent cases of PSP in 2024, which is expected to increase to 268,041 diagnosed prevalent cases by 2029. Currently, there are no approved treatments in the PSP market. The PSP pipeline holds 28 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and seven assets in Phase II...
-
Sector Analysis
Parkinson's Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which...
-
Sector Analysis
Alzheimer’s Disease (AD) Epidemiology Analysis and Forecast to 2033
Alzheimer’s Disease (AD) Report Overview In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.